eFFECTOR Therapeutics (EFTR) Competitors $0.0002 0.00 (0.00%) As of 07/8/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EFTR vs. CLVR, ONCSQ, PXMD, ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, AMPE, and ACABWShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Clever Leaves (CLVR), OncoSec Medical (ONCSQ), PaxMedica (PXMD), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Ampio Pharmaceuticals (AMPE), and Atlantic Coastal Acquisition Corp. II (ACABW). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. Its Competitors Clever Leaves OncoSec Medical PaxMedica 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Ampio Pharmaceuticals Atlantic Coastal Acquisition Corp. II Clever Leaves (NASDAQ:CLVR) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations. Does the media refer more to CLVR or EFTR? In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score. Company Overall Sentiment Clever Leaves Neutral eFFECTOR Therapeutics Neutral Is CLVR or EFTR more profitable? Company Net Margins Return on Equity Return on Assets Clever LeavesN/A N/A N/A eFFECTOR Therapeutics N/A N/A N/A Do insiders & institutionals believe in CLVR or EFTR? 6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings & valuation, CLVR or EFTR? Clever Leaves has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClever Leaves$17.42M0.00-$17.90M-$11.31N/AeFFECTOR TherapeuticsN/AN/A-$35.81M-$13.080.00 Which has more volatility and risk, CLVR or EFTR? Clever Leaves has a beta of 3440.04, suggesting that its share price is 343,904% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500. SummaryClever Leaves beats eFFECTOR Therapeutics on 6 of the 7 factors compared between the two stocks. Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EFTR vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$820.66M$5.50B$8.94BDividend YieldN/A4.84%5.25%4.04%P/E Ratio0.001.0926.9720.11Price / SalesN/A230.52426.02119.76Price / CashN/A23.4436.8257.86Price / Book0.006.137.985.56Net Income-$35.81M-$27.85M$3.16B$248.40M7 Day PerformanceN/A0.67%2.36%4.67%1 Month PerformanceN/A8.48%2.15%6.64%1 Year PerformanceN/A6.72%33.78%21.31% eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.6%$1KN/A0.0010CLVRClever LeavesN/A$0.00flatN/AN/A$1K$17.42M0.00560ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040PXMDPaxMedicaN/A$0.00flatN/A-100.0%$1KN/A0.002ATNFW180 Life SciencesN/A$0.01+2.5%N/A-21.0%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/A-95.6%$0.00N/A0.002AIMDWAinosN/A$0.15flatN/A+74.2%$0.00$106.21K0.0040Gap DownALVOWAlvotechN/A$1.70+13.3%N/A-35.2%$0.00$585.60M0.004AMPEAmpio Pharmaceuticals0.1482 of 5 stars$0.00-96.3%N/A-97.3%$0.00N/A0.0020Gap DownACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02-0.5%N/A-66.2%$0.00N/A0.0015 Related Companies and Tools Related Companies Clever Leaves Alternatives OncoSec Medical Alternatives PaxMedica Alternatives 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Ampio Pharmaceuticals Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EFTR) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
